Subscribe To
CTIC / CTI BioPharma - 3.2x Potential Upside On A De-Risked Asset
CTIC News
By Proactive Investors
May 10, 2023
CTI BioPharma skyrockets on acquisition by Sobi
CTI BioPharma shares added almost 85% on the news that the company would be acquired by Stockholm-based hematology and immunology leader Swedish Orpha more_horizontal
By The Motley Fool
May 10, 2023
Why Shares of CTI BioPharma Are Soaring Wednesday
CTI BioPharma has one FDA-approved therapy, Vonjo, to treat a rare form of bone marrow cancer. The company is being bought at a 89% premium from its c more_horizontal
By InvestorPlace
May 10, 2023
Why Is CTI BioPharma (CTIC) Stock Up 85% Today?
CTI BioPharma (NASDAQ: CTIC ) stock is taking off on Wednesday after the company announced a major acquisition deal with Sobi. This deal has Sobi agre more_horizontal
By Barrons
May 10, 2023
CTI BioPharma Soars After Agreeing $1.7 Billion Sale. Biotech Deals Keep Coming.
Swedish Orphan Biovitrum will buy CTI for $9.10 a share as it looks to expand its rare hematology portfolio. more_horizontal
By Market Watch
May 10, 2023
Swedish Orphan Biovitrum to acquire CTI BioPharma in a deal valued at $1.7 billion
Swedish Orphan Biovitrum AB SE:SOBI on Wednesday announced that it has entered into an agreement to acquire U.S.-based CTI BioPharma Corp. CTIC in a d more_horizontal
By PRNewsWire
May 1, 2023
CTI BioPharma To Report First Quarter 2023 Financial Results and Provide Corporate Update on Thursday, May 11, 2023
SEATTLE , May 1, 2023 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC), a commercial biopharmaceutical company focused on the development and commer more_horizontal
By Seeking Alpha
April 21, 2023
By PRNewsWire
April 12, 2023
CTI BioPharma to Participate in Two Upcoming Investor Conferences in April 2023
SEATTLE, Wash. , April 12, 2023 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC), a commercial biopharmaceutical company focused on the development more_horizontal